Polymeric valproic acid and use thereof

JPWO2022259848A5Inactive Publication Date: 2024-11-19
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023527597
Authority / Receiving Office
JP · JP
Patent Type
Applications
Priority Date
2022-05-23
Filing Date
2022-05-23
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current formulations of valproic acid, used as an antiepileptic and antitumor agent, face challenges such as the need for frequent dosing, side effects like liver damage, and teratogenicity, and lack sustained release mechanisms, necessitating the development of controlled release formulations with carriers and additives.

Method used

A block copolymer of poly(ethylene glycol) and polymerized valproic acid, where valproic acid is covalently bonded via an ester bond, forming nano-sized particles that sustainably release valproic acid in the body, inhibiting protein attachment and modulating its release.

Benefits of technology

The block copolymer effectively sustains valproic acid release, reducing side effects and improving therapeutic outcomes, including antiepileptic and antitumor effects, with enhanced bioavailability and modified chemical properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022259848000001
    Figure 2022259848000001
Patent Text Reader

Abstract

[Problem] To provide a valproic acid derivative for improving the disadvantages or faults associated with using valproic acid itself as medicine. [Solution] Provided is a polymeric compound of valproic acid that is a block copolymer containing a poly(ethylene glycol) segment and a poly(valproic acid vinyl) segment.
Need to check novelty before this filing date? Find Prior Art

Description

Polymerized valproic acid and its use

[0001] The present invention relates to polymerized valproic acid and uses thereof, and more particularly to poly(ethylene glycol)-b-poly(vinyl valproate) copolymers and uses thereof in the medical field.

[0002] The sodium salt of valproic acid (or 2-propylpentanoic acid) (hereinafter sometimes abbreviated as VPA) is currently widely used as an antiepileptic drug, a treatment for the manic state of bipolar disorder, and a migraine attack suppressant. VPA also inhibits the abnormal activation of histone deacetylase (HDAC) and has antitumor effects, leading to several clinical trials. Furthermore, it has been reported to be effective against cancer cachexia (see Am J Physiol Cell Physiol 311: C101-C115, 2016).

[0003] Sodium VPA is used as a first-choice antiepileptic drug, but has problems to be solved, such as the need to maintain a constant blood concentration, the need to remember to take it one or more times a day, the risk of taking large amounts for self-harm, and the presence of side effects such as liver damage and teratogenicity. To solve these problems, sustained-release preparations of sodium valproate that are clinically used are provided that contain carriers or additives commonly used in the art, such as magnesium aluminometasilicate, hydroxypropyl cellulose, magnesium stearate, ethyl cellulose, hypromellose, glycerin fatty acid esters, talc, sucrose, precipitated calcium carbonate, polyoxyethylene (105) polyoxypropylene (5) glycol, powdered gum arabic, titanium oxide, etc. Furthermore, as a modification of the active substance itself, an oral dosage form has been proposed in the past in which an acidic active substance having a free carboxyl group is bonded to a polymer having a tertiary amino group, although valproic acid is not specifically described as the active substance (see JP-A-9-511488).

[0004] In an effort to alleviate some of the above problems, specific film coating agents, sustained-release preparations containing various carriers and additives as mentioned above, and the like have been proposed, but it would be desirable to provide means that can take even more diverse forms.

[0005] In order to solve these problems, the present inventors have investigated chemical derivatization of VPA and found that a block copolymer containing a segment of a polymer in which VPA is covalently bonded to the polymer main chain via an ester bond (sometimes abbreviated as polyVPA) and a segment of poly(ethylene glycol) (sometimes abbreviated as PEG) can sustainedly release VPA in the living body of animals including humans, and exhibit the inherent actions and effects of VPA.

[0006] Therefore, the main features or aspects of the technical matters disclosed in this specification can be listed as follows.

[0007] Aspect 1: A block copolymer comprising a polymerized valproic acid segment represented by the following formula I: wherein A is unsubstituted or substituted C 1 -C 12 The substituents, when substituted, are formyl groups or groups of the formula R 1 R 2 represents a group of CH—, where R 1 and R 2 is independent, C 1 -C 4 Alkoxy or R 1 and R 2 Let's get together -OCH 2 CH 2 O-, -O(CH 2 ) 3 O- or -O(CH 2 ) 4 O—; L represents a linking group; X represents H or C; 1 -C 6 Alkyl, or H or C 1 -C 3 represents alkyl, or H or methyl, Y is H, SH, or S(C=S)-Ph or S(C=S)-OC 1 -C 6m represents an integer of 3 to 100, or 5 to 60, or 5 to 40, or 8 to 40; and n represents an integer of 5 to 10,000, or 10 to 1,000, or 20 to 500.

[0008] Aspect 2: The block copolymer acid of Aspect 1, wherein L is a group represented by the formula: and -(CH2) b S-, and each b is independently an integer from 1 to 5. b When represented by S-, the group is linked along the direction of writing in Formula I. Specifically, the terminal methylene carbon atom of the group is bonded to the terminal oxygen atom (O) of the PEG chain of m repeating units of Formula I, and the other terminal S atom is bonded to the α-terminal carbon atom of the VPA-containing polymer chain of n repeating units of Formula I.

[0009] Aspect 3: Nanoparticles comprising the block copolymer according to aspect 1 or 2.

[0010] Aspect 4: A pharmaceutical preparation comprising the block copolymer of Aspect 1 or 2 as an active ingredient and physiological saline or other additives or diluents commonly used in the art, the pharmaceutical preparation being used, for example, as an antiepileptic drug, a therapeutic agent for treating the manic state of bipolar disorder, a drug for suppressing the onset of migraine attacks, a drug for suppressing diseases caused by the abnormal activity of histone deacetylase (HDAC), or an antitumor agent.

[0011] A block copolymer containing a polymerized valproic acid segment represented by Formula I can itself sustainably release free valproic acid in vivo in animals, including humans. Furthermore, without being bound by theory, the block copolymer can exist in aqueous media (e.g., buffered saline, if necessary) as nanoparticles consisting of a core primarily containing polyVPA segments and a shell primarily containing PEG segments. Due to the presence of highly mobile PEG chains in aqueous media, such particles may inhibit the attachment or access of endogenous proteins (including various enzymes) to the polyVPA segments, thereby inhibiting or regulating the release of free VPA from the particles and the actions of other endogenous substances. Thus, the block copolymer not only exhibits the effects of VPA itself, but may also exhibit excellent effects and efficacies as a pharmaceutical drug distinct from VPA, modifying or enhancing the chemical or biological properties of VPA. Therefore, the present invention may contribute to the enrichment of VPA technology in the fields of medicine and pharmaceuticals, but is not limited thereto.

[0012] The target substance (PEG-b-polyVPA) obtained in Production Example 4 1 1 H NMR spectrum of the nanoparticles (Nano VPA 1 is a particle size distribution diagram showing the results of dynamic light scattering measurement of VPA and Nano in Test Example 1. FIG. 2 is a graph showing the scoring of mouse behavior patterns by administration of a test drug in Test Example 1. FIG. 3 is a graph showing the effect of administration of a test drug on the expression level of brain-derived neurotrophic factor (BDNF) in Test Example 2. FIG. 4 is a graph showing the therapeutic effect (survival rate) of administration of a test drug on C26 cancer-bearing cachexia model mice in Test Example 3. FIG. 5 is a graph showing the change in body weight of model mice by administration of a test drug in Test Example 4. FIG. 6 is a graph showing the change in body weight of model mice by administration of a test drug in Test Example 5. VPA 1 is a graphical representation showing the in vivo kinetics of in mice. Specific description of the invention

[0013] Unless otherwise specified, the terms and conditions used in the present specification regarding the technical matters disclosed herein or the present invention are used as having the meanings and contents commonly used in the relevant technical field. The following explanations can be further added to the technical matters.

[0014] The linking group represented by L in the block copolymer represented by formula I generally means a group containing up to 34, up to 18, or up to 10 carbon atoms, and optionally oxygen and nitrogen atoms. Specific examples thereof include those shown in aspect 2 above. Regarding the technical matters or the present invention, for example, C 1 -C 12 Alkyl means unbranched or branched alkyl having 1 to 12 carbon atoms, including, but not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, hexyl, octyl, decyl, dodecyl, and the like, for example, C 1 -C 6 Alkyl and C 1 -C 3 The alkyl group represents the alkyl groups having 6 or 3 carbon atoms or less among the alkyl groups mentioned above, and OC 1 -C 6 C in alkyl 1 -C 6 The alkyl is the same as above, and C 1 -C 4 Alkoxy is OC 1 -C 4 It has the same meaning as alkyl.

[0015] The block copolymer can exist in an aqueous medium (water or, if necessary, buffered saline, etc.) as nano-sized particles containing a core mainly containing polyVPA segments and mainly containing PEG segments. The nano-sized particles can have, but are not limited to, a mean hydrodynamic diameter in an aqueous solution of the particles measured by dynamic light scattering within the range of 10 nm to 500 nm, 20 nm to 180 nm, or 40 nm to 150 nm.

[0016] The block copolymer can be conveniently produced by protecting one of the terminal OH groups of PEG with a protecting group known in the art if necessary, modifying or altering the other terminal OH group with a group or moiety known in the art (e.g., including a terminal SH or S(=S) alkyl) that can extend the repeating unit of alkyl vinyl valproate (preparation of macromer initiator), and then carrying out an extension (polymerization) reaction known per se using alkyl vinyl valproate at the terminal.

[0017] Nano-sized particles from the block copolymer can be prepared by dissolving the copolymer in a water-miscible organic solvent capable of dissolving the copolymer, and dialyzing the resulting solution against water through a dialysis membrane, e.g., a dialysis membrane with a pore cutoff of 1 kDa to 50 kDa.

[0018] The nanoparticles thus obtained VPA ) can be separated from their solutions or dispersions by, for example, lyophilization, centrifugation, etc., and can be redissolved or suspended in physiological saline, if necessary, to prepare formulations for oral or parenteral administration. When preparing formulations for oral administration, they can be provided as oral tablets or granules, if necessary, using additives, diluents, etc. commonly used in the art. Examples of additives or diluents for oral formulations include, but are not limited to, the aforementioned magnesium aluminometasilicate, hydroxypropyl cellulose, magnesium stearate, ethyl cellulose, hypromellose, glycerin fatty acid esters, talc, sucrose, precipitated calcium carbonate, polyoxyethylene (105) polyoxypropylene (5) glycol, powdered gum arabic, titanium oxide, etc., which are used in sustained-release formulations of sodium valproate, as well as sodium chlorocarmellose and sodium lauryl sulfate. Furthermore, since the nanoparticles can be solubilized or dispersed in water, they can also be prepared as parenteral formulations by solubilizing or dispersing them in physiological saline, buffered as needed.

[0019] The optimal dose of a composition containing such a block copolymer or nanoparticle as an active ingredient cannot be unequivocally determined because it may vary depending on the severity of the disease to be treated and the age, sex, and weight of the patient to be administered. However, the optimal dose can be determined by a specialist, taking into account the dosage and administration of VPA sodium salt currently used in clinical practice, and, if necessary, based on efficacy data obtained through small-scale clinical trials.

[0020] In order to avoid making the explanation complicated, the disclosures of this specification or the present invention will be described in more detail below based on typical examples of the disclosures of this specification or the present invention, but the disclosures or the present invention are not limited to these examples.

[0021] Preparation Example 1: Synthesis of vinyl valproate 25 mL of vinyl acetate (Fujifilm Wako) and 17 mL of valproic acid (Tokyo Chemical Industry Co., Ltd.) were added with 5.6 mg of palladium(II) acetate (Fujifilm Wako) and 17 mg of potassium hydroxide (Fujifilm Wako), and the mixture was allowed to react at room temperature for 3 days. After removing the by-product acetic acid using an evaporator, 25 mL of vinyl acetate was added again, and the mixture was allowed to react for 3 days. After removing the palladium by filtration through Celite, vinyl valproate (20 mL) was obtained by distillation under reduced pressure.

[0022] Production example 2: CH 3 O-(CH 2 CH 2 O) n -CH 2 PhCH 2 Synthesis of Cl(T59) Commercially available CH 3 O-(CH 2 CH 2 O) n Tetrahydrofuran (THF) (100 mL) and 7.2 mL (11.5 mmol, 1.6 M hexane) of butyllithium were added to -H (MW=5,000, 50 g, 10 mmol), followed by the addition of α,α'-dichloroparaxylene (17.5 g, 0.1 mmol) and the reaction was carried out at 50°C for two days. After precipitation in 2-propanol (IPA), the precipitate was dissolved by adding methanol and then precipitated again in IPA. This procedure was repeated three times, and the resulting pale yellow precipitate was dried under reduced pressure to obtain the target substance (47.2 g).

[0023] Production example 3: CH 3 O-(CH 2 CH 2 O) n -CH 2 PhCH 2 S(=S)OCH 2 CH 3 Synthesis of (T64) CH obtained in Production Example 1 3 O-(CH 2 CH 2 O) n -CH 2 PhCH 2 Cl (T59, 30 g) was dissolved in 150 mL of methanol to prepare potassium ethyl xanthate (CH 3 CH 2 OC(=S)SK (0.96 g) was added and reacted at room temperature for 10 minutes. The precipitate was removed by centrifugation, and then the methanol was dried under reduced pressure. The residue was dissolved in chloroform and washed with water. The chloroform layer was separated, dehydrated over anhydrous sodium sulfate, filtered, precipitated in IPA, centrifuged, and dried under reduced pressure to obtain the target substance (27.4 g).

[0024] Production example 4: CH 3 O-(CH 2 CH 2 O) n -CH 2 PhCH 2 (CH 2 CH(OC(=O)CH(CH 2 CH 2 CH 3 ) 2 )) m S(=S)OCH 2 CH 3  Synthesis of (T71) CH synthesized in Production Example 2 3 O-(CH 2 CH 2 O) n -CH 2 PhCH 2 S(=S)OCH 2 CH 3(T64, 5.3 g), azobisisobutyronitrile (57 mg), and vinyl valproate (8.6 g) were added to a flask, and after bubbling with nitrogen for 5 minutes, the mixture was reacted at 60°C for 2 days. The obtained target substance was dissolved in THF, precipitated with IPA, and dried under reduced pressure to obtain the target product (5.4 g). 1 The H NMR spectrum is shown in Figure 1. From the proton peak values ​​shown in Figure 1 (see the data in the table below), the repeat number m of vinyl valproate is derived to be 36.0.

[0025]

[0026] Preparation Example 5: Preparation of Self-Assembled Particles 4.46 g of the copolymer (T71) synthesized above was collected, dissolved in 44.6 mL of dimethylformamide (DMF), placed in a dialysis membrane (MWCO = 3.5 kDa), and dialyzed against 2 L of water. After changing the dialysis water six times every eight hours, dynamic light scattering measurements were performed, confirming the formation of 69 nm particles. The results of the dynamic light scattering measurements are shown in Figure 2.

[0027] Test Example 1: Antiepileptic effect using pentylenetetrazol-induced epilepsy kindling mouse model Pentylenetetrazol (PTZ) was administered intraperitoneally (30 mg / kg) to create a PTZ kindling mouse model (days 1, 3, 5, 8, 10, and 12). The dose was increased to 33 mg / kg (day 15), and then increased by 2% thereafter.

[0028] Kindling model mice were administered with valproic acid or valproic acid particles (Nano) prepared in Production Example 5. VPA The effect of VPA or Nano was analyzed by behavioral observation. VPA was administered on days 0, 2, 4, 7, 9, 11, 14 and 21.

[0029] By scoring the behavioral patterns of the mice, Nano VPA It was confirmed that the administration of the compound suppressed convulsions. The results are shown in Figure 3.

[0030] Scoring was based on the following criteria: Score 1: immobility, exploratory behavior, grooming; Score 2: nodding behavior, short myoclonus; Score 3: long myoclonus, repetitive head movement, repetitive shuddering behavior, stiff tail; Score 4: clonic convulsions, forelimb rotation seizures, hind limb abduction, persistent rearing behavior, falling, Straub's tail lift, kangaroo-like posture; Score 5: tonic convulsions, tonic-clonic convulsions unable to maintain upright posture.

[0031] Test Example 2: Quantification of Brain-Derived Neurotrophic Factor (BDNF) It has been reported that BDNF is elevated in PTZ-induced epilepsy kindling model mice. To determine the effect of drug administration on the expression level of BDNF, the hippocampus of the mice from Test Example 1 was collected and analyzed by RT-PCR. The results are shown in Figure 4. This figure shows that the expression level of BDNF was elevated by PTZ, but the expression level was not significantly different from that of Nano. VPA It can be confirmed that the level is reduced by administration.

[0032] Test Example 3 Valproic acid has been reported to have a therapeutic effect in C26 cancer-bearing cachexia model mice because it has histone deacetylase inhibitory activity. VPA To determine whether similar effects could be confirmed by administering VPA or Nano, we analyzed the effects using a cancer cachexia model mouse. C26 cells, which are used in the cancer cachexia model, were subcutaneously transplanted into Balb / c mice to create tumor-bearing mice. VPA The results are shown in Figure 5. VPA Improved survival rates are observed in the treated group.

[0033] Test Example 4: Toxicity Evaluation VPA and Nano VPA To evaluate the toxicity of VPA and Nano VPA The mice were intraperitoneally administered 500 mg / kg of VPA and the weight change of the mice was observed. The results are shown in Figure 6. From this figure, it can be seen that the VPA-administered group lost weight, but the Nano VPA No weight loss was observed in the treated group.

[0034] Test Example 5: VPA and NanoVPA In vivo kinetics of sodium valproate (VPA) or valproic acid nanoparticles (Nano) were administered to 6-week-old ICR mice (male). VPA ) was administered intraperitoneally to mice at a valproic acid concentration of 400 mg / kg. After a predetermined time, the mice were dissected and blood was collected in heparinized tubes, which were then centrifuged to obtain plasma. The valproic acid concentration in the plasma was analyzed using a Nanopia TDM Valproic Acid (Sekisui Medical). The results are shown in Figure 7. As can be seen from the figure, nanoparticle VPA allows the active ingredient, valproic acid, to remain in the blood for a long period of time, sustaining its effect.

[0035] The modified or altered valproic acid according to the present invention can be applied in the medical and pharmaceutical industries, for example, to exert the effects of valproic acid itself, without the need for specific combinations of various carriers or additives.

Claims

1. A block copolymer containing a polymerized valproic acid segment represented by the following formula I. In the formula, A is unsubstituted or substituted C 1 -C 12 represents alkyl, and when substituted, the substituent is a formyl group or a group of the formula R 1 R 2 CH-, where R 1 and R 2 are independently C 1 -C 4 represents alkoxy or R 1 and R 2 together represent -OCH 2 CH 2 O-, -O(CH 2 ) 3 O- or -O(CH 2 ) 4 O-, L represents a linking group, X represents H or C 1 -C 6 represents alkyl, Y represents H, SH or S(C=S)-Ph or S(C=S)-OC 1 -C 6 represents alkyl, m represents an integer of 3 to 100, and n represents an integer of 5 to 10000.

2. The block copolymer according to claim 1, wherein L is a group selected from the group consisting of the formula: and -(CH 2 ) b S-, and each b is independently an integer of 1 to 5.

3. Nanoparticles containing the block copolymer according to claim 1.

4. A pharmaceutical preparation containing the block copolymer according to claim 1 as an active ingredient and physiological saline or additives or diluents commonly used in the art.

5. The pharmaceutical preparation according to claim 4 for use as a drug selected from an anti-epileptic drug, a therapeutic drug for the manic state of bipolar disorder, an agent for suppressing the onset of migraine attacks, an agent for suppressing diseases caused by abnormal activity of histone deacetylase (HDAC), and an anti-tumor agent.